Merck (MRK) Equity Ratio (2016 - 2026)

Merck has reported Equity Ratio over the past 18 years, most recently at 0.36 for Q1 2026.

Quarterly Equity Ratio fell 15.2% to 0.36 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.36 through Mar 2026, down 15.2% year-over-year, with the annual reading at 0.38 for FY2025, 2.83% down from the prior year.
Equity Ratio was 0.36 for Q1 2026 at Merck, down from 0.38 in the prior quarter.
Over five years, Equity Ratio peaked at 0.44 in Q1 2023 and troughed at 0.35 in Q4 2023.
The 5-year median for Equity Ratio is 0.39 (2024), against an average of 0.39.
Year-over-year, Equity Ratio increased 28.99% in 2022 and then fell 16.38% in 2023.
A 5-year view of Equity Ratio shows it stood at 0.42 in 2022, then fell by 16.38% to 0.35 in 2023, then grew by 12.24% to 0.4 in 2024, then decreased by 2.83% to 0.38 in 2025, then dropped by 7.34% to 0.36 in 2026.
Per Business Quant, the three most recent readings for MRK's Equity Ratio are 0.36 (Q1 2026), 0.38 (Q4 2025), and 0.4 (Q3 2025).

Peer Comparison